Abstract 2433: Multiomic plasma profiling identifies potential signatures of disease progression in early-stage NSCLC

Blood-based markers can be used to non-invasively predict cancer progression after treatment. Here, cell-free DNA (cfDNA) and plasma proteins were evaluated to explore biological signatures of progression in non-small cell lung cancer (NSCLC). Baseline plasma samples (n=24; 16 progressors, 8 non-progressors) were from patients diagnosed in 2004 with stage I-III NSCLC, collected prior to surgical resection, and retrospectively analyzed. Six patients were treated with neoadjuvant therapies, one with adjuvant therapy, and 17 with surgery alone. Progression was defined as a relapse event or death by any cause. Whole-genome sequencing was performed to characterize cfDNA fragments, which reflect nucleosome protection and chromatin state. Transcriptional activation for protein-coding genes was inferred by modeling fragment distribution around each transcription start site. Univariate comparisons of gene activation between progressors and non-progressors and Cox proportional hazard ratios (HRs) were calculated by grouping patients above or below the median of the marker of interest. This analysis revealed IL-1RN, the gene encoding for the IL-1RA antagonist to the IL-1 receptor complex, as the gene most negatively correlated with progression-free survival (PFS) (r = -0.76, p Citation Format: Francesco Vallania, Hayley Warsinske, Peter Ulz, Tzu-Yu Liu, Karen Assayag, Krishnan K. Palaniappan, Mitch Bailey, Irving Wang, David E. Weinberg, Riley Ennis, C Jimmy Lin, Anne-Marie Martin, Nancy Krunic. Multiomic plasma profiling identifies potential signatures of disease progression in early-stage NSCLC [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr 2433.